Bandini, M. et al. Neoadjuvant and adjuvant treatment in high-risk prostate cancer. Expert Rev. Clin. Pharmacol. 11, 425–438 (2018).

Article  CAS  PubMed  Google Scholar 

James, N. D. et al. The Lancet Commission on prostate cancer: planning for the surge in cases. Lancet 403, 1683–1722 (2024).

Article  PubMed  Google Scholar 

Sandhu, S. et al. Prostate cancer. Lancet 398, 1075–1090 (2021).

Article  CAS  PubMed  Google Scholar 

Evans, S. M. et al. Patterns of care for men diagnosed with prostate cancer in Victoria from 2008 to 2011. Med. J. Aust. 198, 540–545 (2013).

Article  PubMed  Google Scholar 

Chang, A. J., Autio, K. A., Roach, M. & Scher, H. I. High-risk prostate cancer – classification and therapy. Nat. Rev. Clin. Oncol. 11, 308–323 (2014).

Article  PubMed  PubMed Central  Google Scholar 

Eggener, S. E. et al. Predicting 15-year prostate cancer specific mortality after radical prostatectomy. J. Urol. 185, 869–875 (2011).

Article  PubMed  PubMed Central  Google Scholar 

Rider, J. R. et al. Long-term outcomes among noncuratively treated men according to prostate cancer risk category in a nationwide, population-based study. Eur. Urol. 63, 88–96 (2013).

Article  PubMed  Google Scholar 

Zumsteg, Z. S. et al. The natural history and predictors of outcome following biochemical relapse in the dose escalation era for prostate cancer patients undergoing definitive external beam radiotherapy. Eur. Urol. 67, 1009–1016 (2015).

Article  PubMed  Google Scholar 

Ferrari, A. C. et al. Molecular load of pathologically occult metastases in pelvic lymph nodes is an independent prognostic marker of biochemical failure after localized prostate cancer treatment. J. Clin. Oncol. 24, 3081–3088 (2006).

Article  CAS  PubMed  Google Scholar 

Lou, D. Y. & Fong, L. Neoadjuvant therapy for localized prostate cancer: examining mechanism of action and efficacy within the tumor. Urol. Oncol. 34, 182–192 (2016).

Article  CAS  PubMed  Google Scholar 

Weber, W. A. et al. What is theranostics? J. Nucl. Med. 64, 669–670 (2023).

Article  PubMed  Google Scholar 

Bostwick, D. G., Pacelli, A., Blute, M., Roche, P. & Murphy, G. P. Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases. Cancer 82, 2256–2261 (1998).

Article  CAS  PubMed  Google Scholar 

O’Keefe, D. S., Bacich, D. J., Huang, S. S. & Heston, W. D. W. A perspective on the evolving story of PSMA biology, PSMA-based imaging, and endoradiotherapeutic strategies. J. Nucl. Med. 59, 1007–1013 (2018).

Article  PubMed  PubMed Central  Google Scholar 

Sweat, S. D., Pacelli, A., Murphy, G. P. & Bostwick, D. G. Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. Urology 52, 637–640 (1998).

Article  CAS  PubMed  Google Scholar 

Calopedos, R. J. S., Chalasani, V., Asher, R., Emmett, L. & Woo, H. H. Lutetium-177-labelled anti-prostate-specific membrane antigen antibody and ligands for the treatment of metastatic castrate-resistant prostate cancer: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 20, 352–360 (2017).

Article  CAS  PubMed  Google Scholar 

Fallah, J. et al. FDA approval summary: lutetium Lu 177 vipivotide tetraxetan for patients with metastatic castration-resistant prostate cancer. Clin. Cancer Res. 29, 1651–1657 (2023).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hofman, M. S. et al. [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet 397, 797–804 (2021).

Article  CAS  PubMed  Google Scholar 

Sartor, O. et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N. Engl. J. Med. 385, 1091–1103 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Versluis, J. M., Long, G. V. & Blank, C. U. Learning from clinical trials of neoadjuvant checkpoint blockade. Nat. Med. 26, 475–484 (2020).

Article  CAS  PubMed  Google Scholar 

Emens, L. A. et al. Cancer immunotherapy: opportunities and challenges in the rapidly evolving clinical landscape. Eur. J. Cancer 81, 116–129 (2017).

Article  CAS  PubMed  Google Scholar 

Rodríguez-Ruiz, M. E., Vanpouille-Box, C., Melero, I., Formenti, S. C. & Demaria, S. Immunological mechanisms responsible for radiation-induced abscopal effect. Trends Immunol. 39, 644–655 (2018).

Article  PubMed  PubMed Central  Google Scholar 

Bolla, M. et al. Duration of androgen suppression in the treatment of prostate cancer. N. Engl. J. Med. 360, 2516–2527 (2009).

Article  CAS  PubMed  Google Scholar 

Denham, J. W. et al. Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial. Lancet Oncol. 12, 451–459 (2011).

Article  CAS  PubMed  Google Scholar 

Pietzak, E. J. & Eastham, J. A. Neoadjuvant treatment of high-risk, clinically localized prostate cancer prior to radical prostatectomy. Curr. Urol. Rep. 17, 37 (2016).

Article  PubMed  Google Scholar 

Tosco, L. et al. Systematic review of systemic therapies and therapeutic combinations with local treatments for high-risk localized prostate cancer. Eur. Urol. 75, 44–60 (2019).

Article  PubMed  Google Scholar 

Aus, G. et al. Three-month neoadjuvant hormonal therapy before radical prostatectomy: a 7-year follow-up of a randomized controlled trial. BJU Int. 90, 561–566 (2002).

Article  CAS  PubMed  Google Scholar 

Dalkin, B. L., Ahmann, F. R., Nagle, R. & Johnson, C. S. Randomized study of neoadjuvant testicular androgen ablation therapy before radical prostatectomy in men with clinically localized prostate cancer. J. Urol. 155, 1357–1360 (1996).

Article  CAS  PubMed  Google Scholar 

Gleave, M. E. et al. Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects. J. Urol. 166, 500–506 (2001).

Article  CAS  PubMed  Google Scholar 

Klotz, L. H. et al. Long-term followup of a randomized trial of 0 versus 3 months of neoadjuvant androgen ablation before radical prostatectomy. J. Urol. 170, 791–794 (2003).

Article  CAS  PubMed  Google Scholar 

Labrie, F. et al. Neoadjuvant hormonal therapy: the Canadian experience. Urology 49, 56–64 (1997).

Article  CAS  PubMed  Google Scholar 

Schulman, C. C., Debruyne, F. M. J. & Forster, G. 4-Year follow-up results of a European prospective randomized study on neoadjuvant hormonal therapy prior to radical prostatectomy in T2–3N0M0 prostate cancer. European Study Group on Neoadjuvant Treatment of Prostate Cancer. Eur. Urol. 38, 706–713 (2000).

Article  CAS  PubMed  Google Scholar